Treatment emergent adverse events of grade ≥3 (nonhematologic, noninfectious)
| Itacitinib (n = 70) . | Grade 3 . |
|---|---|
| Any | 21 (30%) |
| Alanine aminotransferase increased | 5 (7.1%) |
| Hypertension | 4 (5.7%) |
| Syncope | 2 (2.9%) |
| Hypertriglyceridemia | 1 (1.4%) |
| Posterior reversible leukoencephalopathy syndrome | 1 (1.4%) |
| Fall | 1 (1.4%) |
| Subarachnoid hemorrhage | 1 (1.4%) |
| Thrombotic microangiopathy | 1 (1.4%) |
| Hemorrhagic cystitis | 1 (1.4%) |
| Vomiting | 1 (1.4%) |
| Arthralgia and/or myalgia | 2 (2.9%) |
| Hypomagnesemia | 1 (1.4%) |
| Itacitinib (n = 70) . | Grade 3 . |
|---|---|
| Any | 21 (30%) |
| Alanine aminotransferase increased | 5 (7.1%) |
| Hypertension | 4 (5.7%) |
| Syncope | 2 (2.9%) |
| Hypertriglyceridemia | 1 (1.4%) |
| Posterior reversible leukoencephalopathy syndrome | 1 (1.4%) |
| Fall | 1 (1.4%) |
| Subarachnoid hemorrhage | 1 (1.4%) |
| Thrombotic microangiopathy | 1 (1.4%) |
| Hemorrhagic cystitis | 1 (1.4%) |
| Vomiting | 1 (1.4%) |
| Arthralgia and/or myalgia | 2 (2.9%) |
| Hypomagnesemia | 1 (1.4%) |